Precision Medicine in Atrial Fibrillation: Biomarker-Based ABC-AF Risk Scores Fail to Outperform Standard Care
Posted inCardiology Internal Medicine news

Precision Medicine in Atrial Fibrillation: Biomarker-Based ABC-AF Risk Scores Fail to Outperform Standard Care

A large-scale registry-based RCT reveals that tailoring atrial fibrillation treatment using the biomarker-driven ABC-AF risk score does not significantly reduce stroke or death compared to current standard guideline-based care, highlighting the complexities of implementing precision medicine in clinical practice.
Targeted Education Enhances Rhythm Control Adherence in Atrial Fibrillation but Faces Limits in Stroke Prevention: Insights from STEEER-AF
Posted inCardiology Internal Medicine news

Targeted Education Enhances Rhythm Control Adherence in Atrial Fibrillation but Faces Limits in Stroke Prevention: Insights from STEEER-AF

The STEEER-AF cluster-randomized trial reveals that structured professional education significantly boosts adherence to complex rhythm control guidelines in atrial fibrillation, though it shows no significant impact on stroke prevention where baseline performance is already high.
Rethinking First-Line Anticoagulation in Older Adults: Real-World Evidence Challenges Conventional AFib Management
Posted inCardiology Neurology news

Rethinking First-Line Anticoagulation in Older Adults: Real-World Evidence Challenges Conventional AFib Management

A large-scale study of 144,969 Medicare beneficiaries reveals that initial anticoagulant prescriptions for atrial fibrillation may not reduce ischemic stroke risk in patients over 66, while significantly increasing major bleeding hazards, suggesting a need for more nuanced, individualized clinical decision-making.
Albiglutide Reduces Cardiovascular Risks in Patients With Type 2 Diabetes Regardless of Atrial Fibrillation Status: Insights From Harmony Outcomes
Posted inCardiology Diabetes & Endocrinology news

Albiglutide Reduces Cardiovascular Risks in Patients With Type 2 Diabetes Regardless of Atrial Fibrillation Status: Insights From Harmony Outcomes

A sub-analysis of the Harmony Outcomes trial demonstrates that albiglutide consistently reduces major adverse cardiovascular events in Type 2 diabetes patients, irrespective of baseline atrial fibrillation, while showing a trend toward reducing new-onset AF without increasing arrhythmic risk.
Distinct Neuroimaging Signatures: Atrial Fibrillation and Atherosclerosis Drive Divergent Vascular Brain Lesion Patterns
Posted inCardiology Neurology news

Distinct Neuroimaging Signatures: Atrial Fibrillation and Atherosclerosis Drive Divergent Vascular Brain Lesion Patterns

A large-scale comparative study of 3,508 patients reveals that atrial fibrillation and atherosclerosis produce significantly different vascular brain lesions on MRI, with AF favoring non-lacunar infarcts and periventricular white matter changes, while atherosclerosis is linked to lacunar infarcts and micro-bleeds.
Low Potassium Levels Linked to Five-Fold Increase in Daily Atrial Fibrillation Risk: Insights from Continuous Monitoring
Posted inCardiology Internal Medicine news

Low Potassium Levels Linked to Five-Fold Increase in Daily Atrial Fibrillation Risk: Insights from Continuous Monitoring

A post hoc analysis of the LOOP study reveals that hypokalaemia is significantly associated with an increased risk of daily atrial fibrillation, particularly longer episodes. The study highlights that deviations from a patient's individual baseline potassium level are stronger predictors of AF than absolute values.
Is Female Sex a Truly Independent Risk Factor for Stroke in Atrial Fibrillation? Insights from a Large European Cohort
Posted inCardiology news

Is Female Sex a Truly Independent Risk Factor for Stroke in Atrial Fibrillation? Insights from a Large European Cohort

A large European cohort study reveals that while women with atrial fibrillation are less likely to receive anticoagulants and show higher crude thromboembolism rates, female sex is not an independent risk factor after adjusting for comorbidities. The CHA2DS2-VASc score remains superior for clinical reclassification.
No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Stroke in Patients with Atrial Fibrillation and Atherosclerosis: Results from the ATIS‑NVAF Randomized Trial
Posted inCardiology Neurology news

No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Stroke in Patients with Atrial Fibrillation and Atherosclerosis: Results from the ATIS‑NVAF Randomized Trial

In older patients with ischemic stroke/TIA, nonvalvular atrial fibrillation, and atherosclerotic cardiovascular disease, adding a single antiplatelet agent to anticoagulation did not reduce ischemic events but markedly increased bleeding, providing no net clinical benefit versus anticoagulant monotherapy.
No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Ischemic Stroke With Atrial Fibrillation and Atherosclerosis — Higher Bleeding Risk
Posted inCardiology Neurology news

No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Ischemic Stroke With Atrial Fibrillation and Atherosclerosis — Higher Bleeding Risk

In a randomized trial of 316 patients with ischemic stroke/TIA, nonvalvular atrial fibrillation, and atherosclerotic disease, adding an antiplatelet to anticoagulation did not reduce ischemic events but doubled clinically relevant bleeding compared with anticoagulant monotherapy.
Common, Rare and Somatic Genetic Drivers Together Double 5‑Year Atrial Fibrillation Risk: Toward an Integrated Genomic Model (IGM‑AF)
Posted inCardiology news Pathology & Lab Medicine

Common, Rare and Somatic Genetic Drivers Together Double 5‑Year Atrial Fibrillation Risk: Toward an Integrated Genomic Model (IGM‑AF)

A UK Biobank whole‑genome study finds polygenic, rare monogenic, and somatic (CHIP) variants each independently associate with incident atrial fibrillation (AF); combined genomic profiling plus clinical risk (CHARGE‑AF) improves discrimination (C=0.80) and reclassification.
Widespread Anticoagulation Has Lowered Stroke but Not Intracranial Bleeding in the Very Elderly: Insights from a Danish Nationwide AF Cohort (1999–2022)
Posted inCardiology news

Widespread Anticoagulation Has Lowered Stroke but Not Intracranial Bleeding in the Very Elderly: Insights from a Danish Nationwide AF Cohort (1999–2022)

Danish registry data (1999–2022) show large reductions in stroke across age groups with widespread oral anticoagulant (OAC) uptake, but only modest stroke gains and rising intracerebral hemorrhage in patients ≥85 years, highlighting the need for individualized strategies in the very elderly.